Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” SegmentGlobeNewsWire · 2 days ago
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesGlobeNewsWire · Oct 12, 2026
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterGlobeNewsWire · Oct 6, 2026
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the ClinicGlobeNewsWire · Oct 1, 2026
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDGlobeNewsWire · Sep 30, 2026
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology StrategyGlobeNewsWire · Sep 29, 2026Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$3.30 | -$3.40 | Miss |
| May 11, 2026 | -$1.95 | -$6.95 | Miss |
| Mar 13, 2026 | – | -$0.25 | |
| Nov 7, 2025 | -$33.00 | -$0.15 | Beat |
| Aug 13, 2025 | -$39.00 | -$0.61 | Beat |
| May 7, 2025 | -$48.00 | -$2.25 | Beat |